Certificate of Analysis for NR-52246

Acinetobacter baumannii, Strain MRSN 489669

Catalog No. NR-52246

This reagent is the tangible property of the U.S. Government.

Product Description:

Acinetobacter baumannii (A. baumannii), strain MRSN 489669 was isolated in 2014 from a human respiratory sample in Europe as part of a global surveillance program. NR-52246 was deposited as multi-locus sequence type (MLST) ST 2, resistant to amikacin, ampicillin/sulbactam, cefepime, ceftazidime, ceftriaxone, ciprofloxacin, colistin, gentamicin, imipenem, levofloxacin and meropenem, intermediately resistant to tobramycin and sensitive to colistin, trimethoprim/sulfamethoxazole, and tetracycline. NR-52246 was produced by inoculation of the deposited material into Tryptic Soy broth and grown for 1 day at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy agar kolles, which were grown for 1 day at 37°C in an aerobic atmosphere to produce this lot. Quality control testing was completed under propagation conditions unless otherwise noted.

Lot: 70041143 **Manufacturing Date: 13JAN2021**

BEI Resources is committed to ensuring digital accessibility for people with disabilities. This Certificate of Analysis contains complex tables and may not be fully accessible. Please let us know if you encounter accessibility barriers and a fully accessible document will be provided: E-mail: Contact@BEIResources.org. We try to respond to feedback within 24 hours.

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis		
Cellular morphology	Gram-negative rods	Gram-negative rods
Colony morphology	Report results	Circular, convex, entire, smooth and cream
Growth at 44°C ± 2°C[1] 1 day in an aerobic atmosphere on Tryptic Soy agar	Growth	Growth
Motility BBL™ Motility Test Medium w/TTC Indicator for 1 day at 35°C in an aerobic atmosphere	Report results	Non-motile
VITEK® MS (MALDI-TOF)	*A. baumannii*	*A. baumannii* (99.9%)
Antibiotic Susceptibility Profile[2,3]		
Amikacin	Resistant	Resistant (> 256 µg/mL)
Ampicillin/sulbactam	Resistant	Resistant (> 32 µg/mL)
Cefepime	Resistant	Resistant (> 256 µg/mL)
Ceftriaxone	Resistant	Resistant (≥ 64 µg/mL)
Ceftazidime	Resistant	Resistant (≥ 64 µg/mL)
Ciprofloxacin	Resistant	Resistant (≥ 4 µg/mL)
Colistin	Sensitive	Sensitive (≤ 0.25 µg/mL)
Gentamicin	Resistant	Resistant (≥ 16 µg/mL)
Imipenem	Resistant	Resistant (> 8 µg/mL)
Levofloxacin	Resistant	Resistant (> 32 µg/mL)
Meropenem	Resistant	Resistant (> 8 µg/mL)
Trimethoprim/sulfamethoxazole	Sensitive	Sensitive (≤ 0.5 µg/mL)
Tobramycin	Intermediate	Sensitive (2 to 3 µg/mL)[4]
Tetracycline	Sensitive	Sensitive (4 µg/mL)
Genotypic Analysis		
Sequencing of 16S ribosomal RNA gene (~ 1480 base pairs)	≥ 99% sequence identity to *A. baumannii*, strain MRSN 489669 (GenBank: VHEO01000071.1)	99.9% sequence identity to *A. baumannii*, strain MRSN 489669 (GenBank: VHEO01000071.1)
Purity		
7 days at 37°C in an aerobic atmosphere with and without 5% CO_2 on Tryptic Soy agar	Growth consistent with expected colony morphology	Growth consistent with expected colony morphology

BEI Resources
www.beiresources.org

E-mail: contact@beiresources.org
Tel: 800-359-7370
Fax: 703-365-2898

Certificate of Analysis for NR-52246

TEST	SPECIFICATIONS	RESULTS
Viability	Growth	Growth

[1]Growth at 44°C differentiates *A. baumannii* from *A. calcoaceticus and A. pittii*, which do not grow at 44°C.
[2]Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S28 (2018)
[3]Antibiotic susceptibility was tested using a combination of VITEK®2 GN82, Sensititre GNX2F AST and E-test strips.
[4]*A. baumannii*, strain MRSN 489669 was deposited as being intermediately resistant to tobramycin. Repeated antibiotic susceptibility testing determined that for strain MRSN 489669, the tobramycin MIC is 2 to 3 µg per mL, which is interpreted as sensitive. Testing was performed in duplicate.

/Heather Couch/
Heather Couch 04 FEB 2022
Program Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

Support Provided by NIAID

BEI Resources
www.beiresources.org
E-mail: contact@beiresources.org
Tel: 800-359-7370
Fax: 703-365-2898